AU2115799A - Composition and method for treatment and prevention of arthritis and/or autoimmune diseases - Google Patents

Composition and method for treatment and prevention of arthritis and/or autoimmune diseases

Info

Publication number
AU2115799A
AU2115799A AU21157/99A AU2115799A AU2115799A AU 2115799 A AU2115799 A AU 2115799A AU 21157/99 A AU21157/99 A AU 21157/99A AU 2115799 A AU2115799 A AU 2115799A AU 2115799 A AU2115799 A AU 2115799A
Authority
AU
Australia
Prior art keywords
arthritis
prevention
treatment
composition
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21157/99A
Other languages
English (en)
Inventor
Orn Adalsteinsson
Michael J. Daley
Sandra G. Fitzpatrick-Mcelligott
Hellen Chaya Greenblatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DCV Inc
Original Assignee
DCV Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DCV Inc filed Critical DCV Inc
Publication of AU2115799A publication Critical patent/AU2115799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21157/99A 1998-01-19 1999-01-14 Composition and method for treatment and prevention of arthritis and/or autoimmune diseases Abandoned AU2115799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US872898A 1998-01-19 1998-01-19
US09008728 1998-01-19
PCT/US1999/000749 WO1999036077A1 (en) 1998-01-19 1999-01-14 Composition and method for treatment and prevention of arthritis and/or autoimmune diseases

Publications (1)

Publication Number Publication Date
AU2115799A true AU2115799A (en) 1999-08-02

Family

ID=21733320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21157/99A Abandoned AU2115799A (en) 1998-01-19 1999-01-14 Composition and method for treatment and prevention of arthritis and/or autoimmune diseases

Country Status (5)

Country Link
JP (1) JP2002509109A (ja)
CN (1) CN1304312A (ja)
AU (1) AU2115799A (ja)
CA (1) CA2317813A1 (ja)
WO (1) WO1999036077A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043019A2 (en) * 1999-01-19 2000-07-27 Dcv Inc Egg anti-inflammatory composition and method of treating and preventing inflammation
EP1214080B1 (en) * 1999-09-14 2003-11-19 Arkion Life Sciences Glucosamine and hyperimmune egg for reducing inflammation
CA2384246A1 (en) * 1999-09-14 2001-03-22 Orn Adalsteinsson Glucosamine and egg reducing inflammation
US6706267B1 (en) 1999-09-14 2004-03-16 Arkion Life Sciences Llc Glucosamine and egg for reducing inflammation
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2006135915A2 (en) * 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
JP2010501596A (ja) 2006-08-31 2010-01-21 エー・シー・エヌ・１３５ ４９３ ３９１・プロプライエタリー・リミテッド・アズ・トラスティー・フォー・コンカ・ユニット・トラスト 抗体含有組成物を用いた非感染性の病状の処置および／または予防
US20120294954A1 (en) * 2009-12-29 2012-11-22 Hill's Pet Nutrition, Inc Compositions including ginger for the amelioration or prevention of inflammatory conditions
CN103599535B (zh) * 2013-11-15 2016-03-09 陕西建华生物制药有限公司 利用i26免疫蛋粉与中药汤剂制备的外用膏剂
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
EP3490602A4 (en) * 2016-08-01 2020-03-25 Scaled Microbiomics, LLC SYSTEMS AND METHODS FOR MODIFYING THE MICROBIOME TO REDUCE THE RISK OF ILLNESS AND MANIFESTATIONS OF ILLNESS
WO2020147950A1 (en) * 2019-01-16 2020-07-23 Ignova Gmbh Methods of treating fibromyalgia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178671C (zh) * 1996-03-26 2004-12-08 Dcv公司 蛋抗炎成分、分离方法和用途
US5772999A (en) * 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals

Also Published As

Publication number Publication date
WO1999036077A1 (en) 1999-07-22
CN1304312A (zh) 2001-07-18
CA2317813A1 (en) 1999-07-22
JP2002509109A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
EP1021177A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
AU5439996A (en) Compositions and methods for treating pain
AU2327599A (en) Compositions and methods for treating autoimmune diseases
ZA9810788B (en) Method and composition for the treatment and prevention of hyperuricemia
AU7650396A (en) Treatment and prophylaxis of osteoporosis
AU5605398A (en) Novel methods and compositions for treatment of autoimmune diseases
AU9016898A (en) Methods and compositions for treatment of restenosis
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
AU2469599A (en) Methods for the prevention and treatment of fibrosis and sclerosis
AU2115799A (en) Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
AU1556497A (en) Agents for the treatment and prevention of aids
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU2843397A (en) Agent for prophylaxis and treatment of disturbance of visual function
AU3607597A (en) Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases
AU2964199A (en) Prevention and treatment of adhesions
AU4546096A (en) Treatment of waste
AU2420101A (en) Method and composition for the treatment of pain
AU2750297A (en) Methods for prevention and/or treatment of neutropenia
AU4027097A (en) Method of treatment
AU7379296A (en) Method and composition for treatment of osteoporosis
AU5611398A (en) Method of treating or inhibiting neutropenia
AU4799797A (en) Antitumor compositions and methods of treatment
HU9900436D0 (en) Installation and method for the treatment of wine-production efilvents
AU4310397A (en) Treatment of waste

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase